Kindeva Drug Delivery Expands Loughborough, UK, Facilities at Charnwood Campus to Support Growth of Green Propellant Commercialization
Leading global drug-device combination product CDMO Kindeva Drug Delivery (Kindeva) today announced the expansion of their Loughborough, U.K., facilities at the Charnwood Campus Science Innovation and Technology Park. This strategic move by Kindeva supports the growth of green propellant commercialization and secures a dedicated space for the company’s commercial analytical laboratory services team who will be housed at this location after renovations are completed later this year.
The move doubles Kindeva’s U.K. laboratory footprint, expands operations, and will relocate approximately 50 quality control employees from Kindeva’s Loughborough manufacturing site. The company just announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low GWP (Global Warming Potential) propellants at this facility. This additional space also offers potential for further expansion to support future innovation and sustainability opportunities, including development and other supporting capabilities in one location.
“As Kindeva continues to grow worldwide, this expansion is one more step in furthering the commercialization of our customers’ low GWP pMDI products,” says Carl Brookes, Vice President, Manufacturing and Operations – Loughborough at Kindeva. “This is an exciting time for green propellants, and Kindeva is committed to remaining at the forefront of these product transitions supporting a greener planet. As Kindeva continues to develop more sustainable technologies and processes, we are constantly evaluating the potential across all our drug-device platforms and our sites. Our expansion on Charnwood Campus will help Kindeva continue to advance with leading facilities for our employees who are tasked with ensuring some of the highest standards of quality and safety for the products we make, and ultimately improving the health of patients we serve.”
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604987016/en/
Contact information
Holli Kroeker
+1 308-338-2358
pr@scorrmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lineage Announces Closing of Initial Public Offering27.7.2024 00:19:00 EEST | Press release
Lineage, Inc. (the “Company”) (Nasdaq: LINE) today announced the closing of its underwritten initial public offering of 56,882,051 shares of its common stock at a public offering price of $78.00 per share. The net proceeds from the offering were approximately $4.2 billion, after deducting underwriting discounts and commissions and estimated expenses payable by the Company. The Company intends to use the net proceeds received from the offering to repay borrowings outstanding under its delayed draw term loan, repay borrowings outstanding under its revolving credit facility, fund one-time cash grants to certain of its employees in connection with this offering and estimated cash to pay tax withholding obligations associated with stock grants and redeem its Series A preferred stock. Following such uses, the Company expects to use the remaining net proceeds for general corporate purposes, which may include the repayment of additional borrowings outstanding under its revolving credit facilit
Introducing LEDGER FLEX — Easy, Secure Self-Custody, Free From Compromise26.7.2024 18:15:00 EEST | Press release
Ledger, the world leader in Digital Asset security for consumers and enterprises, today launched for sale Ledger Flex, its second new product launch in 2024. Released during Ledger’s tenth anniversary, Ledger Flex and the previously released Ledger Stax mark the inception of a new generation of Ledger hardware, featuring secure E Ink® touchscreen displays powered by Ledger’s Secure OS. Ledger Flex is available to purchase today on Ledger.com and through our retail partners around the world for $249, shipping immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726882083/en/ Ledger Flex™ (Photo: Business Wire) Ledger Flex marks the new standard for Ledger devices, featuring NFC and a secure E Ink® touchscreen, at an attractive price point. Ledger Flex is an homage to the iconic black and steel motif featured on Ledger devices for a decade, a reminder of Ledger’s heritage of uncompromising security. Its high-resoluti
LambdaTest Unveils Live Inspect for Enhanced App Automation Testing26.7.2024 18:00:00 EEST | Press release
LambdaTest, a leading cloud-based unified testing platform, introduces its latest offering, the Live Inspect feature for app automation testing. This tool empowers developers and testers to optimize their app automation processes with unparalleled live debugging capabilities directly from the LambdaTest automation dashboard. The Live Inspect feature allows users to interact with their automated test devices in real time, enhancing the efficiency and effectiveness of automated tests. With features such as real-time navigation, detailed UI element inspection, and screenshot capture, teams can now troubleshoot issues directly as they arise with their automation scripts, moving beyond mere video playback to active engagement with their applications. LambdaTest’s Live Inspect features include real-time interaction, which allows users to navigate their apps, inspect UI elements, capture screenshots, and generate unique custom xpaths while the automation script runs seamlessly. The enhanced U
Radico Khaitan comes onboard as the Official Partner for the first India House at The Paris 2024 Olympics26.7.2024 16:04:00 EEST | Press release
India House, the inaugural country house for the nation at the Paris 2024 Olympic Games, announces Radico Khaitan as the Official Partner. India House will serve as a home away from home for athletes as well as fans, commemorating 100 years since India first competed at the Olympic Games under the Indian Olympic Association in 1920. Radico Khaitan’s alliance with India House reaffirms the Company’s deep-rooted commitment to India’s growth and its vision to showcase the nation’s rich heritage and luxurious culture to the global audience. With a surge in sporting enthusiasm across India, it becomes imperative to empower our athletes and celebrate their success wherever they compete. Radico Khaitan is dedicated to boosting national morale at the Olympics and championing our athletes on the grand global stage. Through its contributions to India House, Radico Khaitan aims to spotlight India's opulence, culture, and legacy, fostering solidarity and pride among Indians worldwide in support of
Fujirebio Launches the Fully Automated Lumipulse ® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu26.7.2024 14:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. “In 2023 we already introduced two new important neuro assays for RUO-based detection of Neurofilament Light (NfL) and pTau 217,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.” The Lumipulse G GFAP assay will allow the scienti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom